Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

BACKGROUND: In statin trials, men and women derived similar relative risk reductions in cardiovascular events per 39 mg/dL low‐density lipoprotein cholesterol (LDL‐C) reduction. We explored whether lower LDL‐C levels and greater LDL‐C percentage reductions than those achieved with statins are associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallejo‐Vaz, Antonio J., Ginsberg, Henry N., Davidson, Michael H., Eckel, Robert H., Cannon, Christopher P., Lee, L. Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Ray, Kausik K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222947/
https://www.ncbi.nlm.nih.gov/pubmed/30371190
http://dx.doi.org/10.1161/JAHA.118.009221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222947/
https://www.ncbi.nlm.nih.gov/pubmed/30371190
http://dx.doi.org/10.1161/JAHA.118.009221

Ejemplares similares